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Abstract
Objective
Magnesium sulphate is recommended by international guidelines to prevent eclampsia
among women with pre-eclampsia, especially when it is severe, but fewer than 70% of such
women receive magnesium sulphate. We aimed to identify variables that prompt Canadian
physicians to administer magnesium sulphate to women with pre-eclampsia.
Methods
Data were used from the Canadian Perinatal Network (2005–11) of women hospitalized at
<29 weeks’ who were thought to be at high risk of delivery due to pre-eclampsia (using
broad Canadian definition). Unadjusted analyses of relative risks were estimated directly
and population attributable risk percent (PAR%) calculated to identify variables associated
with magnesium sulphate use. A multivariable model was created and a generalized esti-
mating equation was used to estimate the adjusted RR that explained magnesium sulphate
use in pre-eclampsia. The adjusted PAR% was estimated by bootstrapping.
Results
Of 631 women with pre-eclampsia, 174 (30.1%) had severe pre-eclampsia, of whom 131
(75.3%) received magnesium sulphate. 457 (69.9%) women had non-severe pre-eclam-
spia, of whom 291 (63.7%) received magnesium sulphate. Use of magnesium sulphate
among women with pre-eclampsia could be attributed to the following clinical factors (PAR
%): delivery for ‘adverse conditions’ (48.7%), severe hypertension (21.9%), receipt of ante-
natal corticosteroids (20.0%), maternal transport prior to delivery (9.9%), heavy proteinuria
(7.8%), and interventionist care (3.4%).
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Conclusions
Clinicians are more likely to administer magnesium sulphate for eclampsia prophylaxis in
the presence of more severe maternal clinical features, in addition to concomitant antenatal
corticosteroid administration, and shorter admission to delivery periods related to transport
from another institution or plans for interventionist care.
Introduction
Magnesium sulphate is effective for treatment of eclampsia [1]. The Magpie Trial demon-
strated that magnesium sulphate could halve the rate of seizures among women with pre-
eclampsia [2]. Magnesium sulphate was equally effective for severe and non-severe pre-
eclampsia, although treatment of women with non-severe pre-eclampsia required a high num-
ber-needed-to-treat (NNT) to prevent one seizure (i.e., 100 vs. 50) and at a higher cost (US
$21,202 vs. $12,942) compared to severe pre-eclampsia [3]. In well-resourced settings, this has
led to recommendations to administer magnesium sulphate to all women with ‘severe’ pre-
eclampsia, and consider doing so to women with non-severe disease. In under-resourced set-
tings, similar recommendations have been made by the World Health Organization (WHO),
citing that magnesium sulphate may not be available for all women [4].
In the seminal Magpie Trial, the definition of severe pre-eclampsia was based on severe
hypertension and heavier proteinuria (3+), or less severe hypertension associated with find-
ings of ‘imminent eclampsia’ for which there is no standard definition but is usually inter-
preted as central nervous system symptoms or hyperreflexia [2]. This definition of severe
disease does not align well with current international definitions between which there is also
substantial variability from country to country, and within countries over time [5].
In Canada, the 1997 national pregnancy hypertension guidance, pre-eclampsia was broadly
defined as gestational hypertension with proteinuria or an adverse condition(s) that consisted
of relevant maternal symptoms, signs, or abnormal laboratory tests, or relevant fetal manifesta-
tions; ‘severe’ pre-eclampsia was not defined [6–8]. In the 2008 update, ‘severe’ pre-eclampsia
was defined as gestational hypertension with proteinuria and an ‘adverse condition(s)’ as
defined previously [9]. In the 2014 update, ‘severe’ pre-eclampsia was defined according to
the presence of an indication for delivery—a severe complication(s) for the mother or fetus
[10,11]. Magnesium sulphate was recommended for all women in 1997, and then in 2008 and
2014, all women with ‘severe’ pre-eclampsia, with consideration to be given to also administer-
ing magnesium sulphate to women with ‘non-severe’ disease.
In the international Pre-eclampsia Integrated Estimate of RiSk (PIERS) study that aimed to
find predictors of adverse maternal outcome among women admitted to hospital with pre-
eclampsia, magnesium sulphate was administered to only 62% of 261 women who were both
hospitalized with pre-eclampsia and suffered an adverse maternal outcome that would meet
any international definition of ‘severe’ disease, suggesting that clinicians may be using criteria
other than strict definitions of ‘severe’ or ‘non-severe’ disease to guide therapy [12]. The aim of
our study was to identify factors that influence magnesium sulphate administration to women
with pre-eclampsia in Canadian tertiary perinatal centres.
Materials and methods
The Canadian Perinatal Network (CPN) is a database of women admitted to 16 tertiary care
centres in Canada (August 2005 to March 2011) at 22+0 to 28+6 weeks gestation because of
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threatened preterm birth. These women were admitted with one or more of: spontaneous preterm
labour with contractions, preterm pre-labour rupture of membranes (PPROM), short cervix with-
out contractions, prolapsing membranes, gestational hypertension, intrauterine fetal growth
restriction (IUGR), or antepartum haemorrhage. This study was approved centrally as a quality
assurance project at the University of British Columbia (H05-70359) and at each participating
site’s Research Ethics Board. Details of the CPN study have been published previously [13].
In this analysis, we included women who presented to a participating CPN site with pre-
eclampsia/eclampsia (before 29 weeks) as their primary indication for admission. Pre-eclamp-
sia was defined broadly as gestational hypertension with proteinuria, or one or more of rele-
vant pre-eclampsia maternal symptoms, signs or abnormal laboratory tests; this definition was
consistent with the 1997, 2008, and 2014 national guidance in Canada, as published by the
Society of Obstetricians and Gynaecologists of Canada (SOGC) [5–11].
The primary outcome was magnesium sulphate administration for pre-eclampsia/eclamp-
sia, antenatally or postnatally (S1 File).
Descriptive statistics were used to compare the characteristics of women who received mag-
nesium sulphate, with those who did not, using the Chi-square (categorical variables) and
Mann-Whitney U tests (continuous variables), with a p-value <0.05 considered to be statisti-
cally significant. As the primary outcome of magnesium sulphate use was a common occur-
rence, univariable analyses of relative risks (RR) were estimated directly using generalized
linear models with a binomial distribution and a log link instead of calculating odds ratios
(OR) (as an OR would be expected to overestimate the RR with a common outcome).
For inclusion in the multivariable model, we tested candidate variables that were either
associated with magnesium sulphate use at p<0.10 or differed among women treated with
magnesium sulphate (vs. those who were not) by an absolute amount that could be clinically
important and identify lost therapeutic opportunities that could be addressed to improve mag-
nesium sulphate use and outcomes. As such, variables that occurred infrequently (among <5
women) were not included. Continuous variables, such as maternal age and blood pressure,
were collapsed into meaningful categories, and some inter-related outcomes were combined
(e.g., fetal syndrome of pre-eclampsia) in order to avoid problems of model convergence. The
variables were reviewed to identify those with the highest RR and eliminate those that were
likely to be highly intercorrelated with other included variables to create the most parsimoni-
ous model. The final list of variables was determined through expert opinion from obstetric
medicine, obstetrics, and epidemiology.
A final generalized estimating equation was used to account for the multicentre design of
CPN and estimate the adjusted RR that explained magnesium sulphate use. Adjusted Popula-
tion Attributable Risk percent (PAR%) was calculated for each variable in the model to identify
determinants of magnesium sulphate use. PAR% for a variable was interpreted as the propor-
tion of magnesium sulphate use that was attributable to that variable, noting that the PAR%
for different variables are not additive [14]. The 95% CI for the adjusted PAR% were estimated
by bootstrapping methods [15].
All statistical analyses were performed using R statistical software (www.r-project.org).
In sensitivity analyses, we explored the impact of: (i) adding as a determinant pre-eclampsia
severity defined according to the 2014 SOGC HDP guidelines [9,10], defined in detail in
Table A in S2 File; and (ii) excluding variables that were assumed to have been present prior
to magnesium sulphate use, but that were not time-stamped: (a) severe hypertension that was
replaced by severe hypertension therapy (with parenteral hydralazine or labetalol, or nifedi-
pine capsules or intermediate-acting tablets) that was time-stamped, and (b) severe hyperten-
sion and heavy proteinuria; and (iii) restricting the analysis to intrapartum/postpartum
therapy to examine the impact of variables that were antepartum but not time-stamped.
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Results
There were 631 eligible women who were at 22+0 and 28+6 weeks gestation when admitted to
one of 16 CPN participating tertiary perinatal centres for pre-eclampsia care. 422 (66.9%)
women received magnesium sulphate for eclampsia prophylaxis.
Table 1 presents the baseline maternal and pregnancy characteristics of the women
included. Women who received magnesium sulphate (compared with those who did not)
differed according to most admission maternal and pregnancy characteristics. These women
were more frequently: younger in age, nulliparous, had a history of gestational hypertension,
and demonstrated more severe maternal clinical features of pre-eclampsia, in terms of
higher BP, heavier proteinuria, and more frequent serious maternal end-organ complica-
tions (for details, see Table B in S2 File). Of note, these women treated with magnesium sul-
phate were less likely to have fetal manifestations and stillbirth. They also had shorter
admission to delivery intervals and delivered at an earlier gestational age and more often by
Caesarean.
Table 2 outlines the 15 variables considered for the final model of factors associated with
magnesium sulphate use in pre-eclampsia. The following variables were excluded: (i) prior
venous thromboembolism (as it was very uncommon); (ii) prior gestational hypertension (as it
would not apply to nulliparous women); (iii) gestational age on admission or delivery (as the
difference was not clinically significant, and the majority of these women delivered very pre-
term); (iv) peak systolic and diastolic BP (in favour of severe hypertension); (v) any, as opposed
to heavy, proteinuria (because almost all women had some proteinuria and there was a larger
difference between groups in heavy proteinuria); (vi) whether this was the woman’s first
admission and latency from enrolment to delivery, both of which were accounted for by inter-
ventionist care; and (vii) mode of delivery (as the key decision point is the timing of delivery as
spontaneous or induced). Also, fetal manifestations of pre-eclampsia were combined into one
‘fetal syndrome’ variable, and delivery for maternal symptoms and signs combined to create a
parsimonious model.
The adjusted RR and PAR% and associated 95% confidence intervals show that there were
six factors that were independently associated with magnesium sulphate use. The strongest
related to maternal symptoms and signs of maternal disease (PAR% of 48.6%) or severe hyper-
tension (PAR% of 21.9%).
In sensitivity analyses, the final model changed little. The SOGC classification of the sever-
ity of pre-eclampsia [i.e., 190 (30.1%) women with ‘severe’ pre-eclampsia among whom 139
(73.2%) received magnesium sulphate, and 441 (69.9%) with non-severe pre-eclampsia of
whom 283 (64.2%) received magnesium sulphate] was not independently associated with mag-
nesium sulphate use when added to the final model (Table C in S2 File). Replacement of
severe hypertension with severe hypertension therapy caused heavy proteinuria (which had
been of borderline statistical significance before, but significant) to be dropped, and singleton
pregnancy to emerge (that had been of borderline statistical significance before, but not signifi-
cant) (Table D in S2 File). When severe hypertension and heavy proteinuria were excluded,
singleton pregnancy again emerged as significant (Table E in S2 File). Only when analysis was
restricted to antepartum predictors and intrapartum/postpartum magnesium sulphate delivery
did maternal transport prior to delivery and interventionist care fall out of the model, but
delivery for the fetal syndrome of pre-eclampsia emerged as a significant negative predictor
(i.e., of NOT receiving magnesium) (Table F in S2 File); the direction of effect was the same in
the final model and other sensitivity analyses, but they were not statistically significant. Confi-
dence intervals were wide.
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Table 1. Demographic and clinical characteristics of women with severe/non-severe pre-eclampsia according to MgSO4 use (N = 631).
MgSO4 use N = 422 No MgSO4 use N = 209 Unadjusted RR (95% CI) p-value
Demographic and clinical characteristics in index pregnancy
Maternal age (yr) 30.0 [26.0, 35.0] 33.0 [29.0, 37.0] - <0.001
24 76 (18.0%) 17 (8.1%) 1.26 (1.09, 1.45)
25–29 108 (25.6%) 44 (21.1%) 1.09 (0.94, 1.27)
30–34 115 (27.3%) 62 (29.7%) Reference
35 123 (29.1%) 86 (41.1%) 0.91 (0.77, 1.06)
Pre-existing medical conditions
Pre-existing hypertension 87 (20.6%) 57 (27.3%) 0.88 (0.76, 1.02) 0.076
Diabetes mellitus 9 (2.1%) 10 (4.8%) 0.70 (0.44, 1.13) 0.113
Venous thromboembolism 2 (0.5%) 4 (1.9%) - 0.097
Nulliparous 298 (70.6%) 121 (57.9%) 1.22 (1.07, 1.38) 0.002
Singleton pregnancy 396 (93.8%) 182 (87.1%) 1.40 (1.06, 1.85) 0.006
Previous gestational hypertension 60 (14.2%) 52 (24.9%) 0.84 (0.69, 1.02) 0.001
Gestational age at enrolment 26.9 [25.3, 28.0] 26.6 [25.1, 27.9] - 0.098
Blood pressure
Peak sBP 180 [168, 193] 168 [158, 180] - <0.001
Peak dBP 107 [100, 114] 100 [95, 109] - <0.001
sBP160 or dBP110 mmHg 388 (91.9%) 157 (75.1%) 1.80 (1.38, 2.35) <0.001
Proteinuria 408 (96.7%) 190 (90.9%) 1.61 (1.08, 2.40) 0.004
3+ on dipstick or3g/d 335 (79.4%) 127 (60.8%) 1.41 (1.20, 1.65) <0.001
Maternal Interventions prescribed
Bedrest 311 (73.7%) 165 (78.9%) 0.91 (0.81, 1.03) 0.179
Interventionist carea 111 (26.3%) 15 (7.2%) 1.43 (1.30, 1.57) <0.001
Maternal transport prior to delivery 268 (63.5%) 80 (38.3%) 1.42 (1.25, 1.60) <0.001
Any antihypertensive therapy 388 (91.9%) 187 (89.5%) 1.11 (0.89, 1.38) 0.380
Antenatal corticosteroids 376 (89.1%) 156 (74.6%) 1.52 (1.22, 1.89) <0.001
Progress after admission & outcomes
Severe maternal complications (one/more)b 163 (38.6%) 59 (28.2%) 1.16 (1.04, 1.29) 0.013
Fetal syndrome of pre-eclampsia (one/more) 271 (64.2%) 149 (71.3%) 0.90 (0.81, 1.01) 0.09
Abnormal umbilical artery Doppler 116 (27.5%) 72 (34.4%) - 0.089
Oligohydramnios 51 (12.1%) 29 (13.9%) - 0.611
Birthweight <10th centile 130 (30.8%) 92 (44.0%) - 0.001
Stillbirth 48 (11.4%) 28 (13.4%) - 0.545
Delivered on 1st admission 372 (88.2%) 143 (68.4%) - <0.001
Indication for delivery
Uncontrolled hypertension 169 (40.0%) 81 (38.8%) 1.02 (0.91, 1.14) 0.821
Maternal pre-eclampsia symptoms 338 (80.1%) 75 (35.9%) <0.001
Other maternal signs or abnormal pre-eclampsia lab results 275 (65.2%) 55 (26.3%) 3.33 (2.48, 4.46) <0.001
Latency, enrolment to delivery (d) 3.0 [1.0, 7.0] 3.0 [11.0, 34.0] - <0.001
Gestational age at delivery (wk) 27.7 [26.0, 28.7] 28.7 [27.0, 31.6] - <0.001
Mode of delivery
Vaginal 76 (18.0%) 55 (26.3%) 0.84 (0.72, 0.98) 0.021
Caesarean 346 (82.0%) 155 (74.2%) 1.18 (1.01, 1.38) 0.029
Spontaneous labour 8 (1.9%) 24 (11.5%) 0.49 (0.29, 0.83) <0.001
Neonatal death prior to or during NICU admission 32 (7.6%) 13 (6.2%) - 0.644
Data presented as N(%) or median [IQR]
dBP (diastolic blood pressure), NICU (neonatal intensive care unit), sBP (systolic blood pressure), wk (weeks)
a Pregnancies that were not expectantly managed.
b See Table B in S2 File for details of severe maternal complications.
https://doi.org/10.1371/journal.pone.0189966.t001
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Discussion
Summary of results
In a large cohort of women with pre-eclampsia who were hospitalized at<29 weeks to Cana-
dian tertiary perinatal centres, magnesium sulphate was used suboptimally for eclampsia pro-
phylaxis. Even among those with serious maternal complications that constitute indications
for delivery and meet all international criteria for ‘severe’ pre-eclampsia, magnesium sulphate
was administered in 75.3% (131/174) of cases. Magnesium sulphate for eclampsia prophylaxis
was more likely to be administered when: (i) antenatal corticosteroids had also been adminis-
tered; (ii) delivery was indicated based on maternal symptoms or signs, or there was severe
hypertension or heavy proteinuria; or (iii) the clinician had been managing the pre-eclampsia
for a shorter period of time and was proceeding with interventionist care. The model was
essentially unchanged in sensitivity analyses, including those that added into the model the
Canadian definition of ‘severe’ pre-eclampsia, and singleton pregnancy replacing heavy pro-
teinuria in analyses where it was excluded, though both of these are unmodifiable clinical
factors.
Table 2. Determinants included in the final model for magnesium sulphate use in all pre-eclampsiaa.
Determinants Adjusted RR [95%
CI]
PAR% [95% CI]
Demographic and clinical characteristics in index
pregnancy
Maternal age (yr)
24 1.11 [1.05, 1.17] 1.42 [-0.55, 2.88]
25–29 1.03 [0.96, 1.11] 0.73 [-3.42, 3.15]
30–34 Reference Reference
35 1.01 [0.92, 1.11] 0.35 [-5.05, 3.95]
Pre-existing hypertension 0.93 [0.86, 0.997] -1.82 [-4.79, 0.85]
Nulliparity 1.08 [1.00, 1.16] 4.88 [-2.32, 11.61]
Singleton pregnancy 1.23 [0.99, 1.53] 17.38 [-3.34,
38.03]
Pre-eclampsia severity criteria
Severe hypertension (sBP160 or dBP110) 1.34 [1.08, 1.67] 21.92 [9.27, 35.99]
Heavy proteinuria (3+ or3.0g/d) 1.12 [1.01, 1.24] 7.82 [0.18, 17.12]
Delivery for maternal symptoms or sign(s) of pre-eclampsia 2.73 [1.30, 5.72] 48.67 [41.40,
56.36]
Severe maternal complications 1.02 [0.95, 1.10] 0.86 [-2.16, 3.86]
Fetal syndrome of pre-eclampsiab 0.94 [0.89, 0.99] -4.58 [-11.28, 2.02]
Maternal interventions prescribed
Maternal transport prior to delivery 1.22 [1.12, 1.32] 9.87 [4.63, 15.00]
Interventionist care 1.21 [1.17, 1.25] 3.41 [1.92, 4.95]
Antenatal corticosteroids 1.31 [1.09, 1.58] 20.01 [9.78, 32.39]
Spontaneous labour initiation 0.72 [0.26, 2.02] -2.00 [-7.83, 0.48]
BP (blood pressure), dBP (diastolic BP), PAR% (population attributable risk), RR (relative risk), sBP (systolic
BP)
a Variables highlighted in yellow demonstrated significant, independent associations with magnesium
sulphate use.
b Includes one/more of abnormal Doppler of umbilical artery, oligohydramnios, intrauterine fetal growth
restriction, birthweight <10th centile, and stillbirth.
https://doi.org/10.1371/journal.pone.0189966.t002
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How the results compare with the existing literature
Underutilization of magnesium sulphate among women with ‘severe’ pre-eclampsia is consis-
tent with other studies, whether they be single-centre studies in Canada [16] or multicentre
international studies [12]. Variation in opinion about what constitutes ‘severe’ pre-eclampsia
is reflected in between-protocol variation in 22 Canadian tertiary hospitals and within-hospital
differences in protocol and practice [17].
The seminal Magpie Trial that demonstrated the effectiveness of magnesium sulphate for
eclampsia prevention when clinicians focussed on treating women with symptoms of ‘immi-
nent eclampsia’, severe hypertension, or heavy proteinuria [2]. Our results suggest that clini-
cians are heeding maternal symptoms and severe hypertension, but there is room for
improvement. Also, clinicians appear to be influenced by additional factors, such as maternal
signs other than severe hypertension as indications for delivery, medication (concomitant
administration of antenatal corticosteroids), transport prior to delivery, and interventionist
care. Further, although singleton pregnancy was not always a significant result, the high PAR%
indicates that clinicians may also be influenced by it.
Strengths and limitations
The strength of this study includes a large population dataset with representation from 16 ter-
tiary centres across Canada. As well, because the outcome was common (i.e., the majority
received magnesium sulphate), we were able to directly estimate the relative risk. However,
there are also limitations to our study. First, there were variables with uncertain time points,
such as peak BP measurements and proteinuria; however, exclusion of these factors from
modelling did not change the significance of the other factors in the final model, and restrict-
ing the model to intrapartum and postpartum delivery had lower power. Also, the results are
based on a high-risk population of women with pre-eclampsia who were admitted to hospital
at<29 weeks; although it is possible that our overall rates of use may be higher than rates of
use at term, we do not expect that clinical factors associated with magnesium sulphate would
vary with gestational age.
Conclusions
Most women with pre-eclampsia are being treated with magnesium sulphate for eclampsia
prevention. As in Magpie, women are identified, although not in optimal numbers, based on
symptoms and severe hypertension, but clinicians are using additional factors on which to
base treatment decisions. Future work should focus on which women with pre-eclampsia may
benefit most from magnesium sulphate if the drug is not administered to all women with pre-
eclampsia for reasons of cost (in all settings) or drug availability (in under-resourced settings).
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S2 File. Table A. Definitions of adverse conditions and severe complications of pre-eclampsia
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Determinants of magnesium sulphate use in severe and non-severe pre-eclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0189966 December 22, 2017 7 / 10
hypertension.
Table E. Sensitivity analyses excluding severe hypertension and heavy proteinuria from the
model.
Table F. Sensitivity analyses restricting to intrapartum and postpartum administration of mag-
nesium sulphate.
(DOC)
Acknowledgments
An abstract related to the contents of this manuscript was presented at the XIX World Con-
gress of the International Society for the Study of Hypertension in Pregnancy (ISSHP), in New
Orleans, US in October 2014.
We would like to thank Jennifer Hutcheon for her guidance and helpful review of the analy-
ses and interpretation. We also thank the members of the CPN collaborative group:
Steering Committee: Laura A. Magee (St. George’s University of London, London UK),
Robert Liston (University of British Columbia, Vancouver BC), Victoria Allen (Dalhousie
University, Halifax NS), Mark Ansermino (University of British Columbia, Vancouver BC),
Franc¸ois Audibert (Universite´ de Montre´al, Montreal QC), Rollin Brant (University of British
Columbia, Vancouver BC), Emmanuel Bujold (Universite´ Laval, Que´bec QC), Joan Crane
(Memorial University of Newfoundland, St. John’s NF), Nestor Demianczuk (University of
Alberta, Edmonton AB), KS Joseph (University of British Columbia, Vancouver BC), Jean-
Marie Moutquin (Universite´ de Sherbrooke, Sherbrooke QC), Bruno Piedboeuf (Universite´
Laval, Que´bec QC), Graeme Smith (Queen’s University at Kingston, Kingston ON), Peter von
Dadelszen (St. George’s University of London, London UK), Mark Walker (University of
Ottawa, Ottawa ON), Wendy Whittle (University of Toronto, Toronto ON)
Database programmers, analysts, and coordinator: Larry Li, Tang Lee, Dane A. De Silva
CPN Site Investigators: Laura A. Magee (BC Women’s Hospital & Health Centre, Vancou-
ver BC), Jerome Dansereau (Victoria General Hospital, Victoria BC), Carmen Young (Royal
Alexandra Hospital, Edmonton AB), Stephen Wood (Foothills Medical Centre, Calgary AB),
Femi Olatunbosun (Royal University Hospital, Saskatoon SK), George Carson, (Regina Gen-
eral Hospital, Regina SK), Graeme Smith (Kingston General Hospital, Kingston ON), Renato
Natale (London Health Sciences Centre, London ON), Wendy Whittle (Mount Sinai Hospital,
Toronto ON), Mark Walker (The Ottawa Hospital, Ottawa ON), Francois Audibert (Centre
Hoˆspitalier Universitaire Sainte-Justine, Montre´al QC), Jean-Charles Pasquier (Centre Hoˆspi-
talier Universitaire de Sherbrooke, Sherbrooke QC), Emmanuel Bujold (Centre Hoˆspitalier de
L’Universite´ Laval, Que´bec City QC), Victoria Allen (IWK Health Centre, Halifax NS), Joan
Crane (Women’s Health Program, Eastern Health, St. John’s NL)
Author Contributions
Conceptualization: Dane A. De Silva, Peter von Dadelszen.
Data curation: Peter von Dadelszen, the Canadian Perinatal Network (CPN) Collaborative
Group, Laura A. Magee.
Formal analysis: Dane A. De Silva, Lily Proctor, Meghan McCoach, Tang Lee.
Funding acquisition: Peter von Dadelszen, Laura A. Magee.
Investigation: Dane A. De Silva, Peter von Dadelszen, the Canadian Perinatal Network (CPN)
Collaborative Group, Laura A. Magee.
Methodology: Dane A. De Silva, Laura A. Magee.
Determinants of magnesium sulphate use in severe and non-severe pre-eclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0189966 December 22, 2017 8 / 10
Project administration: Peter von Dadelszen, the Canadian Perinatal Network (CPN) Collab-
orative Group, Laura A. Magee.
Resources: Peter von Dadelszen, the Canadian Perinatal Network (CPN) Collaborative
Group, Laura A. Magee.
Supervision: Peter von Dadelszen, Laura A. Magee.
Writing – original draft: Dane A. De Silva, Laura A. Magee.
Writing – review & editing: Dane A. De Silva, Lily Proctor, Peter von Dadelszen, Meghan
McCoach, Tang Lee.
References
1. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence
from the Collaborative Eclampsia Trial. Lancet 1995; 345(8963):1455–1463. PMID: 7769899
2. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and
their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled
trial. Lancet 2002 Jun 1; 359(9321):1877–1890. PMID: 12057549
3. Simon J, Gray A, Duley L, Magpie Trial Collaborative Group. Cost-effectiveness of prophylactic magne-
sium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Mag-
pie Trial. BJOG 2006 Feb; 113(2):144–151. https://doi.org/10.1111/j.1471-0528.2005.00785.x PMID:
16411990
4. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and
eclampsia. 2011. Available from: apps.who.int/iris/bitstream/10665/44703/1/9789241548335_eng.pdf.
5. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a
systematic review of international clinical practice guidelines. PLoS One 2014 Dec 1; 9(12):e113715.
https://doi.org/10.1371/journal.pone.0113715 PMID: 25436639
6. Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hyperten-
sion Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disor-
ders in pregnancy. CMAJ 1997 Sep 15; 157(6):715–725. PMID: 9307560
7. Moutquin JM, Garner PR, Burrows RF, Rey E, Helewa ME, Lange IR, et al. Report of the Canadian
Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of
hypertensive disorders in pregnancy. CMAJ 1997 Oct 1; 157(7):907–919. PMID: 9327800
8. Rey E, LeLorier J, Burgess E, Lange IR, Leduc L. Report of the Canadian Hypertension Society Con-
sensus Conference: 3. Pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ 1997
Nov 1; 157(9):1245–1254. PMID: 9361646
9. Magee LA, Helewa M, Moutquin JM, von Dadelszen P, Hypertension Guideline Committee, Strategic
Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. Diagnosis,
evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008
Mar; 30(3 Suppl):S1–48. https://doi.org/10.1016/S1701-2163(16)32776-1 PMID: 18817592
10. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, SOGC Hypertension Guideline Committee.
Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive sum-
mary. J Obstet Gynaecol Can 2014 Jul; 36(7):575–576.
11. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Preg-
nancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of
pregnancy. Pregnancy Hypertens 2014 Apr; 4(2):105–145. https://doi.org/10.1016/j.preghy.2014.01.
003 PMID: 26104418
12. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Cote AM, et al. Prediction of
adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lan-
cet 2011 Jan 15; 377(9761):219–227. https://doi.org/10.1016/S0140-6736(10)61351-7 PMID:
21185591
13. Magee LA, von Dadelszen P, Allen VM, Ansermino JM, Audibert F, Barrett J, et al. The Canadian Peri-
natal Network: a national network focused on threatened preterm birth at 22 to 28 weeks’ gestation. J
Obstet Gynaecol Can 2011 Feb; 33(2):111–120. https://doi.org/10.1016/S1701-2163(16)34795-8
PMID: 21352628
14. Morgenstern H. Attributable fractions. In: Boslaugh S, editor. Encycolpedia of Epidemiology, Volume 2
Thousand Oaks, CA: Sage Publications; 2008. p. 56–63.
Determinants of magnesium sulphate use in severe and non-severe pre-eclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0189966 December 22, 2017 9 / 10
15. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public
Health 1998 Jan; 88(1):15–19. PMID: 9584027
16. Girard P, Quirion A, Bureau Y, Sauve´ N. Magnesium sulphate for eclampsia prevention: Quality of care
evaluation in a tertiary centre in Que´bec, Canada. Obstetric Medicine: The Medicine of Pregnancy 2014
June 01; 7(2):71–76.
17. De Silva DA, Sawchuck D, von Dadelszen P, Basso M, Synnes AR, Liston RM, et al. Magnesium Sul-
phate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian
Tertiary Perinatal Centres. J Obstet Gynaecol Can 2015 Nov; 37(11):975–987. PMID: 26629718
Determinants of magnesium sulphate use in severe and non-severe pre-eclampsia
PLOS ONE | https://doi.org/10.1371/journal.pone.0189966 December 22, 2017 10 / 10
